Citius Oncology secures $25M credit facility and $11.5M warrant exercise to boost LYMPHIR commercialization.

Citius Oncology has entered a senior secured credit facility with Avenue Capital Group for up to $25 million, including an initial $10 million tranche, to support the commercialization of its FDA-approved cancer drug LYMPHIR. Concurrently, the company raised approximately $11.5 million through the exercise of warrants by a healthcare-focused investor. These financings provide Citius Oncology with enhanced financial flexibility to expand sales, market access, and manufacturing efforts for LYMPHIR, targeting relapsed or refractory cutaneous T-cell lymphoma. The funds will also support working capital and general corporate purposes as the company scales its commercial infrastructure.